Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Aarti Drugs Ltd

| Quarterly Financial Results Q3 FY 2025-26

NEUTRAL SENTIMENT

Report Source

⬤3rd Feb 26

Summary : Aarti Drugs reported mixed Q3/9M FY26 results with revenue growth, slight profit dip, declared interim dividend, and commenced new plant operations.

Quarterly Report Analysis & Insights

Financial Disclosures

  1. Detailed breakdown includes cost of materials, stock-in-trade, inventories, employee benefits, finance, depreciation, other expenses.
  2. Standalone revenue from operations: Q3 FY26 Rs. 52,880 lakhs, 9M FY26 Rs. 1,62,871 lakhs.
  3. Consolidated revenue from operations: Q3 FY26 Rs. 60,171 lakhs, 9M FY26 Rs. 1,84,501 lakhs.
  4. Post buyback, paid-up share capital reduced to Rs. 91.27 crores.
  5. Both standalone and consolidated results presented.
  6. Consolidated includes three subsidiaries: Pinnacle Life Science, Aarti Specialty Chemical, Pinnacle Chile SpA.

Corporate Overview

  1. Expanding domestic markets.
  2. Focus on export marketing.
  3. Assessing impact of new government labor codes.
  4. Manufacturer of bulk drugs and chemicals.
  5. Operates solely in the pharmaceuticals segment.
  6. Factual and compliant, announcing financial results and board decisions.
  7. Serves various formulation players in the market.
  8. Pharmaceuticals segment only.
  9. New manufacturing plant at Sayakha, Gujarat commenced operations September 2025.
  10. New manufacturing plant at Sayakha, Gujarat commenced operations.

Risk Factors

  1. New labor codes impact assessment.
  2. Potential adjustments from new regulations.

Key Drivers

  1. New Gujarat plant commenced operations.
  2. Interim dividend declared for shareholders.
  3. Senior management roles redefined for growth.
  4. Expanding domestic and export market focus.

Auditor’s Report

  1. Unmodified opinion on standalone and consolidated financial results.

Board Commentary

  1. Declared interim dividend of Rs. 2 per equity share (20%).
  2. Detailed impact assessment of new labor codes.
  3. Impact assessment of new labor codes in progress.
  4. Completed buyback of 6,65,000 equity shares for Rs. 59.85 crores.

Corporate Governance

  1. Adherence to Code of Ethics and ethical requirements.
  2. Auditors confirmed compliance with ethical requirements regarding independence.
  3. Audit Committee and Nomination & Remuneration Committee mentioned.

Management Discussion & Analysis

Future Strategy

  1. Organizational alignment with redefined senior management roles.

Industry Overview

  1. Company operates solely in pharmaceuticals sector.

Macroeconomic Outlook

  1. Government of India notified four new Labour Codes.

Operational Focus Areas

  1. Focus on marketing, export marketing, and purchase efficiency.

Performance Drivers

  1. Expanding domestic and export markets.
  2. Strategic sourcing and procurement initiatives.

Critical Risks

  1. Uncertain impact of new labor codes.
Aarti Drugs Ltd (AARTIDRUGS) Quarterly Report Analysis & Insights | Dhanarthi